TABLE 2.
Biomarker | CN vs. MCI | CN vs. AD | MCI vs. AD | CN vs. MCI/AD |
Total protein (μg/mL)† | <0.0001 | 0.02 | 0.1 | <0.0001 |
CST-C (μg/mL)† | 0.02 | 0.26 | 0.01 | 0.50 |
CST-C/total protein ratio† | 0.07 | 0.002 | 0.28 | 0.0008 |
IL-1RN (μg/mL)† | 0.01 | 0.63 | 0.02 | 0.32 |
IL-1RN/total protein ratio† | 0.30 | 0.01 | 0.17 | 0.03 |
SFN (μg/mL)† | 0.03 | 0.55 | 0.03 | 0.48 |
SFN/total protein ratio† | 0.10 | 0.04 | 0.67 | 0.02 |
MMP-9 (μg/mL)† | 0.04 | 0.0002 | 0.50 | 0.0003 |
MMP-9/total protein ratio† | 0.44 | 0.002 | 0.11 | 0.02 |
Hp (μg/mL)† | 0.003 | 0.02 | 0.51 | 0.0007 |
Hp/total protein ratio† | 0.21 | 0.08 | 0.41 | 0.06 |
†Unadjusted p-values shown from log transformed data of absolute concentrations and their ratio to total protein.
AD, Alzheimer’s disease; CN, Cognitively Normal; CST-C, Cystatin-C; Hp, Haptoglobin; IL-1RN, Interleukin-1 receptor antagonist protein; Matrix metalloproteinase 9, MMP-9; MCI, Mild cognitive impairment; SFN, Stratifin; vs., versus.